Uncategorized

Antitrust regulators have reached a deal with Welsh, Carson, Anderson and Stowe that doesn’t penalize the private equity firm for rolling up the market for anesthesia services in Texas, but tries to prevent it from happening again.

Healthcare fraud investigations accounted for more than half of the Department of Justice’s settlements and judgments in 2024, which totaled north of $2.9 billion.

CEOs from Medtronic, Intuitive Surgical, Boston Scientific and Dexcom were on hand this week in San Francisco to discuss the year ahead at the J.P. Morgan Healthcare Conference.

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea for the slow, healthy recovery of the industry at large.

Last year was a record year for health system divestitures, and Kaufman Hall expects to see more in 2025.

The data suggest the high dose nearly closes the efficacy gap with Zepbound.

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the 15 products to be subject to IRA-prescripted price negotiations for Medicare this year.

Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare negotiations or not. CMS has until June 1 to send an initial offer for the adjusted prices.

The shape of AI regulation will be uncertain under the Trump administration this year, while healthcare companies will continue bolstering cyber defenses to withstand increasing attacks, experts say.

BD invested $10 million last year to increase manufacturing capacity. The recent expansion has created more than 200 jobs.